Atherosclerosis Research
Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.
Atherosclerosis Research Products Targets
- PI 3-kinase (22)
- HMG-CoA Reductase (8)
- Matrix Metalloprotease (16)
- LXR-like Receptor (6)
- Elastase (1)
- Cell Adhesion Molecule (21)
- Lipoxygenase (8)
- Leukotriene and Related Receptor (13)
- Others (7)
- Cytokine Receptor (4)
- Cyclooxygenase (24)
- IRAK (1)
- PPARγ (16)
- PPARδ (5)
- PPARα (7)
- Angiotensin-Converting Enzyme (8)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Urotensin-II Receptor (8)
- Angiotensin AT2 Receptor (3)
- Angiotensin AT1 Receptor (9)
- SREBP (2)
- GPBA Receptor (3)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Cytokine (15)
- Platelet-Activating Factor (PAF) Receptor (5)
Products for Atherosclerosis Research - Page 22
- Cat.No. Product Name Information/Activity
-
BCC5010
PD123319
PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
-
BCC5921
CGP 42112
CGP-42112(CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.
-
BCC7413
ZK 756326
874911-96-3
-
BCC7572
BMS CCR2 22
BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC50 of 5.1 nM) and potent functional antagonism (calcium flux IC50 of 18 nM and chemotaxis IC50 of 1 nM).
-
BCC6029
BX 471
BX471 (ZK-811752) is an orally active, potent and selective non-peptide CCR1 antagonist with a Ki of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.
-
BCC6047
C 021 dihydrochloride
Potent CCR4 antagonist
-
BCC5909
DAPTA
DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
-
BCC1646
INCB 3284 dimesylate
INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC50 of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.
-
BCC7422
J 113863
J-113863 is a potent and selective CCR1 (CD18) antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect.
-
BCC3675
Maraviroc
Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.


